Novel C7-Substituted Coumarins as Selective Monoamine Oxidase Inhibitors: Discovery, Synthesis and Theoretical Simulation

Molecules. 2019 Nov 5;24(21):4003. doi: 10.3390/molecules24214003.

Abstract

There is a continued need to develop new selective human monoamine oxidase (hMAO) inhibitors that could be beneficial for the treatment of neurological diseases. However, hMAOs are closely related with high sequence identity and structural similarity, which hinders the development of selective MAO inhibitors. "Three-Dimensional Biologically Relevant Spectrum (BRS-3D)" method developed by our group has demonstrated its effectiveness in subtype selectivity studies of receptor and enzyme ligands. Here, we report a series of novel C7-substituted coumarins, either synthesized or commercially purchased, which were identified as selective hMAO inhibitors. Most of the compounds demonstrated strong activities with IC50 values (half-inhibitory concentration) ranging from sub-micromolar to nanomolar. Compounds, FR1 and SP1, were identified as the most selective hMAO-A inhibitors, with IC50 values of 1.5 nM (selectivity index (SI) < -2.82) and 19 nM (SI < -2.42), respectively. FR4 and FR5 showed the most potent hMAO-B inhibitory activity, with IC50 of 18 nM and 15 nM (SI > 2.74 and SI > 2.82). Docking calculations and molecular dynamic simulations were performed to elucidate the selectivity preference and SAR profiles.

Keywords: BRS-3D; in silico pharmacokinetic predictions; molecular dynamic simulations; monoamine oxidase (MAO) inhibitors; subtype selectivity.

MeSH terms

  • Brain / drug effects
  • Brain / metabolism
  • Caco-2 Cells
  • Cell Line, Tumor
  • Coumarins / chemistry*
  • Coumarins / pharmacology*
  • Humans
  • Molecular Docking Simulation
  • Monoamine Oxidase / metabolism*
  • Monoamine Oxidase Inhibitors / chemistry*
  • Monoamine Oxidase Inhibitors / pharmacology*
  • Protein Binding
  • Structure-Activity Relationship

Substances

  • Coumarins
  • Monoamine Oxidase Inhibitors
  • Monoamine Oxidase